Swedish model Elsa Hosk sparks backlash for recreating Princess Diana's iconic revenge dress for Halloween - The model ...

Elevate your golf game with this Lilly ... Pulitzer skort in a vibrant pink hue, offering UPF 50 protection and stylish comfort for your time on the course. Embrace a breezy vibe with this smocked ...

Far from a mere festivity, Halloween calls us to look beyond this world to the eternal one, uniting ourselves in prayer with the holy souls who have gone before us. Candles lit amid celebrations ...

When you purchase through links on our site, we may earn an affiliate commission. Dress shirts may not be the most exciting of garments - but they are one of the fundamental basics every guy ...

The US economy continued to expand at a robust pace in the third quarter as household purchases accelerated and the federal government ramped up defense spending. Hiring jumped by the most in more ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Eli Lilly (NYSE:LLY) shares fell ~9% in the premarket on Wednesday, sending ADRs of its rival Novo Nordisk (NVO) lower after the U.S. drugmaker missed Street forecasts with its Q3 2024 financials ...

Shares of Eli Lilly and Co. slumped toward their biggest selloff in more than three years on Wednesday, after the drugmaker reported third-quarter results that missed expectations, due to big ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...